摘要
目的评价生血宝合剂治疗肝硬化致食管胃底静脉曲张破裂出血后贫血的有效性与安全性。方法 140例肝硬化致食管胃底静脉曲张破裂出血后贫血患者,随机分为观察组和对照组,各70例。对照组仅给予促红细胞生成素(促红素)治疗,观察组在对照组治疗基础上联合生血宝合剂治疗。对比两组治疗前和治疗后血红蛋白水平,临床疗效和不良反应发生情况。结果治疗后,观察组的血红蛋白水平为(117.820±7.944)g/L,对照组的血红蛋白水平为(95.450±7.129)g/L,比较差异具有统计学意义(P<0.01)。观察组的治愈率为48.57%,显著高于对照组的11.43%,差异具有统计学意义(P<0.01);观察组的临床获益率为91.43%,显著高于对照组的50.00%,差异具有统计学意义(P<0.01)。无脾功能亢进患者中,观察组的治愈率为59.57%,显著高于对照组的16.00%,差异具有统计学意义(P<0.01);观察组的临床获益率为95.74%,显著高于对照组的52.00%,差异具有统计学意义(P<0.01)。脾功能亢进患者中,观察组的治愈率为26.09%,显著高于对照组的0,差异具有统计学意义(P<0.05);观察组的临床获益率为82.61%,显著高于对照组的45.00%,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论生血宝合剂可有效纠正肝硬化致食管胃底静脉曲张破裂出血后贫血的状态,且不增加治疗过程中出现的不良反应,安全性较高,具有显著的临床价值。
Objective To evaluate the effectiveness and safety of Shengxuebao mixture in the treatment of anemia after esophageal-gastric varices bleeding caused by liver cirrhosis. Methods A total of 140 patients with anemia after esophageal-gastric varices bleeding caused by liver cirrhosis were randomly divided into observation group and control group, with 70 cases in each group. The control group was treated with erythropoietin, and the observation group was treated with Shengxuebao mixture on the basis of the control group. Comparison were made on hemoglobin level before and after treatment, clinical efficacy and occurrence of adverse reactions between the two groups. Results After treatment, the observation group had hemoglobin level as(117.820±7.944) g/L,which was(95.450±7.129) g/L in the control group, and the difference was statistically significant(P<0.01).The observation group had significantly higher cure rate as 48.57% than 11.43% in the control group, and the difference was statistically significant(P<0.01). The observation group had significantly higher clinical benefit rate as 91.43% than 50.00% in the control group, and the difference was statistically significant(P<0.01). In patients without hypersplenism, the observation group had significantly higher cure rate as 59.57% than 16.00% in the control group, and the difference was statistically significant(P<0.01). The observation group had significantly higher clinical benefit rate as 95.74% than 52.00% in the control group, and the difference was statistically significant(P<0.01). In patients with hypersplenism, the observation group had significantly higher cure rate as 26.09% than 0 in the control group, and the difference was statistically significant(P<0.05). The observation group had significantly higher clinical benefit rate as 82.61% than 45.00% in the control group, and the difference was statistically significant(P<0.05). Both groups had no statistically significant difference in incidence of adverse reactions(P>0.05). Conclusion Shengxuebao mixture can effectively correct anemia after esophageal-gastric varices bleeding caused by cirrhosis without increasingadverse reactions in the course of treatment. It has high safety and significant clinical value.
作者
杨和验
黄进团
YANG He-yan;HUANG Jin-tuan(Huizhou Third People' s Hospital,Huizhou 516000,China)
出处
《中国实用医药》
2019年第16期12-14,共3页
China Practical Medicine
